INTRODUCTION

Uterine sarcomas account about <1% of all uterine malignancies and arises from mesodermal structures like muscles and connective tissues. Mesenchymal tumors of the uterus with cytological and architectural features reminiscent of endometrial stromal cells are classified as endometrial stromal tumors. The recent World Health Organization Classification of Tumors of the Breast and Female Genital Organs divides stromal neoplasm into benign endometrial stromal nodule (ESN), Low Grade endometrial stromal sarcoma (LGESS), High Grade Endometrial Stromal Sarcoma (HSESS) and undifferentiated endometrial sarcoma. High grade endometrial stromal sarcoma is very rare especially among the young population.

CASE

A 40-year-old para 2 lady with regular previous menstrual cycle came with menometrorrhagia for 3 months and endometrial biopsy report as low grade endometrial stromal neoplasia. She had no significant medical, surgical history and family history. She was nonsmoker and nonalcoholic with contraceptive history of depot medroxyprogesterone acetate 10 years ago. Her general and vital signs were normal. Cervix bled on touch with speculum blade; and uterus and adnexae were normal. MRI revealed endometrial thickness of 9 mm with fluid in endometrial cavity and low signal nodule about 1.1 ×2cm in the fundal region of endometrial cavity. [Figure-1]
nt is kept under regular follow up.

Figure-2: 40x with atypia  Figure-3: 40x showing areas of focal necrosis

COMMENTS

Endometrial stromal sarcoma is very rare malignant tumor contributing approximately 10% of all uterine sarcomas but only 0.2% of all uterine malignancy and is usually presented in late stage. In 2003, the WHO changed the diagnostic criteria after which the term endometrial sarcoma was restricted to an invasive endometrial stromal neoplasm with a distinct histologic appearance with very good prognosis, while the term undifferentiated endometrial stromal sarcoma was introduced for those with more pleomorphic appearance with prominent tumor necrosis and very poor prognosis.

HG-ESS is a rare pathological type of uterine sarcoma. The mean age of ESS ranges between 45 and 55 years however there is a case report of HG-ESS in a patients of 21 years. The patients may present with the common symptoms of abnormal uterine bleeding, pelvic pain and uterine mass or endometrial polyp. Though stage of the disease, age and complete surgery are mentioned to be most important prognostic factors by some authors, information regarding the natural course, prognostic factors and optimal treatment for HG-ESS is very limited at present. The disease is often misdiagnosed as uterine leiomyoma or endometrial carcinoma prior to surgery due to lack of characteristics image and clinical manifestations.

Gross appearance of HG-ESS may show a polypoid intracavity mass or intramural mass, poorly circumscribed with myometrial invasion and cut section may reveal extensive areas of hemorrhage and necrosis. Microscopically, the tumor consists predominantly high grade round, epitheloid cells with scant or moderate amounts of eosinophilic cytoplasm, containing round to oval vesicular nuclei with irregular nuclear contours and nucleoli. Tongue like myometrial invasion forming nested growth, mitotic activity of more than 10 per high power field along with the areas of necrosis is also peculiar feature of HG-ESS.

Surgery including hysterectomy with salpingo-oophorectomy and resection of any extraterine disease (if present) is the mainstay treatment of ESS. Complete staging and cytoreductive surgery in HG-ESS have shown to improve disease free survival (DFS). Though some have stated no additional advantage of oophorectomy during hysterectomy, however oophorectomy in the patients with retained ovaries have shown to improve the DFS of 100% when compared to 25% among the patients without oophorectomy. However it can be an option for pre-menopausal women with stage I disease. The prognostic significance of complete lymphadenectomy still remains controversial. Zhang et al have found that lymph node and omentum dissection play no role in prognosis.

External pelvic irradiation has been widely used as adjuvant treatment for HS-ESS in order to decrease the recurrence; however it hasn’t shown any pathbreaking result regarding the overall survival (OS) concluding that adjuvant radiotherapy may be speculated to decrease local recurrence but its impact on the overall survival is questionable. Use of adjuvant chemotherapy (doxorubicin, ifosphamide and cisplatin) is reasonable in the particularly aggressive disease as the recurrence pattern of HG-ESS is often distant and visceral. The addition of chemotherapy to radiotherapy have shown to improve 3 year survival rate and overall survival though the results did not reach statistical significance.

Hence, the use of adjuvant radiotherapy and chemotherapy in the management of HS-ESS deserves further investigation.

CONCLUSIONS

Highgrade endometrial stromal sarcoma is the rarest of the rare uterine sarcoma. Preoperative diagnosis is a challenge as the clinical and radiological features resemble to that of fibroid uterus or polyp. Complete surgical staging is the primary treatment and also important prognostic factor for disease free survival along with age at diagnosis and stage of the disease.

REFERENCES


4. Angelos D, Anastasios L, Dimosthenis M, Roxani D, Alexia P, Konstantinos D. Endometrial stromal sarcoma presented as endometri-


